{
    "ticker": "COCP",
    "name": "Cocrystal Pharma, Inc.",
    "description": "Cocrystal Pharma, Inc. is a biotechnology company focused on developing novel antiviral therapies targeting a range of viral diseases. Founded in 2007, the company leverages its proprietary technology platform to create and optimize small molecule therapeutics. Cocrystal's lead product candidates are designed to treat infections caused by viral pathogens, including influenza and hepatitis C. The company's innovative approach is based on its unique understanding of viral replication mechanisms, allowing it to develop therapies that can effectively inhibit viral replication. Cocrystal is committed to advancing the science of antiviral drug development and addressing unmet medical needs in infectious diseases. With a robust pipeline and strategic partnerships, Cocrystal aims to bring transformative therapies to market that can significantly improve patient outcomes and quality of life. The company's mission is to create a healthier future through innovative antiviral solutions, fostering advancements in medical science and patient care.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Bothell, Washington, USA",
    "founded": "2007",
    "website": "https://www.cocrystalpharma.com",
    "ceo": "James Martin",
    "social_media": {
        "twitter": "https://twitter.com/CocrystalPharma",
        "linkedin": "https://www.linkedin.com/company/cocrystal-pharma/"
    },
    "investor_relations": "https://ir.cocrystalpharma.com",
    "key_executives": [
        {
            "name": "James Martin",
            "position": "CEO"
        },
        {
            "name": "M. M. (Mike) McGowan",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Antiviral Therapies",
            "products": [
                "CC-31244 (for influenza)",
                "CC-122 (for hepatitis C)"
            ]
        }
    ],
    "seo": {
        "meta_title": "Cocrystal Pharma, Inc. | Innovative Antiviral Therapies",
        "meta_description": "Explore Cocrystal Pharma, Inc., a leader in antiviral drug development. Discover our innovative therapies targeting influenza and hepatitis C.",
        "keywords": [
            "Cocrystal Pharma",
            "Antiviral Therapies",
            "Biotechnology",
            "Hepatitis C",
            "Influenza"
        ]
    },
    "faq": [
        {
            "question": "What is Cocrystal Pharma known for?",
            "answer": "Cocrystal Pharma is known for developing innovative antiviral therapies for viral diseases."
        },
        {
            "question": "Who is the CEO of Cocrystal Pharma?",
            "answer": "James Martin is the CEO of Cocrystal Pharma, Inc."
        },
        {
            "question": "Where is Cocrystal Pharma headquartered?",
            "answer": "Cocrystal Pharma is headquartered in Bothell, Washington, USA."
        },
        {
            "question": "What are Cocrystal Pharma's main products?",
            "answer": "Cocrystal's main products include CC-31244 for influenza and CC-122 for hepatitis C."
        },
        {
            "question": "When was Cocrystal Pharma founded?",
            "answer": "Cocrystal Pharma was founded in 2007."
        }
    ],
    "competitors": [
        "GILD",
        "VRTX",
        "SNY"
    ],
    "related_stocks": [
        "AMGN",
        "REGN",
        "BMY",
        "JNJ"
    ]
}